Bavarian plans to send RSV vaccine to phase III, prepares equity raise

A commitment to initiate a phase III study of its vaccine candidate against the RS virus in the first half of 2022 has led Bavarian Nordic to prepare a share issue involving up to 10 percent of its registered capital.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Bavarian Nordic has committed to initiating a phase III study of its vaccine against RSV in the first half of 2022. However, sufficient funding must first be secured through a fundraising round where 10 percent of registered share capital is up for grabs, the company reports in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs